<DOC>
	<DOCNO>NCT00984802</DOCNO>
	<brief_summary>This study conduct assess safety CMX-2043 solution intravenous ( IV ) injection , evaluate efficacy basis change see cardiac biomarkers continuous electrocardiography ( ECG ) monitoring . Additionally , correlation levels/changes biomarkers pharmacokinetic evaluation drug explore .</brief_summary>
	<brief_title>Safety Efficacy CMX-2043 Subjects Undergoing Coronary Reperfusion Therapy</brief_title>
	<detailed_description />
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<criteria>Subjects stable coronary artery disease undergo elective PCI . Female subject childbearing potential . Absence ST segment depression &gt; 1.0 mm absence ST elevation &gt; 1.0 mm lead baseline 12lead ECG . subject CKMB troponinT level low upper limit normal . Subjects free acute injury illnesses . Subjects unstable angina ( angina rest , worsen frequency , duration angina ) sign unstable coronary artery disease . Subjects MI within 14 day prior PCI procedure . Subjects condition contraindicate PCI ( e.g . coagulopathy , valvular disease , PVD ) . Subjects history TIA/stroke within 90 day intracranial bleed . Subjects creatinine clearance â‰¥ 1.5 time upper limit normal . Subjects active history psychiatric disorder likely limit validity consent participate study limit ability comply protocol requirement . Subjects history alcohol drug abuse . Subjects document history human immunodeficiency virus ( HIV ) , Hepatitis B ( HBsAg ) Hepatitis C ( HCV ) virus positive . Subjects uncorrected clinically significant abnormality clinical laboratory test investigator opinion interfere study conduct . Subject chronic disease consider anesthetist unfit surgery and/or opinion investigator increase risk study obscure interpretation result . Subjects participate clinical study within 1 month currently participate clinical study investigational agent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2011</verification_date>
</DOC>